• 1. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 2. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 3. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 4. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 5. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Quinazolines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Benzodiazines Quinazolines

Recent Advances in the Study of 7-Bromo-2,4,6-trichloro-8-fluoroquinazoline (CAS: 1698028-11-3)

7-Bromo-2,4,6-trichloro-8-fluoroquinazoline (CAS: 1698028-11-3) is a fluorinated quinazoline derivative that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential applications in drug discovery and development. Recent studies have focused on its synthesis, structural modifications, and biological activities, particularly in the context of targeting specific enzymes and pathways involved in various diseases.

A recent study published in the Journal of Medicinal Chemistry (2023) explored the synthetic routes for 7-Bromo-2,4,6-trichloro-8-fluoroquinazoline, emphasizing its role as a versatile intermediate for the development of kinase inhibitors. The researchers demonstrated that this compound could be efficiently synthesized through a multi-step process involving halogenation and fluorination reactions, with a high yield and purity. The study also highlighted the compound's stability under various conditions, making it suitable for further derivatization.

In another study, researchers investigated the biological activity of 7-Bromo-2,4,6-trichloro-8-fluoroquinazoline and its derivatives against cancer cell lines. The results, published in Bioorganic & Medicinal Chemistry Letters (2023), revealed that the compound exhibited potent inhibitory effects on certain tyrosine kinases, which are often overexpressed in cancerous tissues. The study suggested that structural modifications at the 2, 4, and 6 positions could enhance selectivity and reduce off-target effects, paving the way for the development of more effective anticancer agents.

Additionally, a collaborative research effort between academic and industrial laboratories reported the use of 7-Bromo-2,4,6-trichloro-8-fluoroquinazoline in the design of novel antimicrobial agents. The study, featured in European Journal of Medicinal Chemistry (2023), demonstrated that derivatives of this compound showed promising activity against drug-resistant bacterial strains, including MRSA and Pseudomonas aeruginosa. The researchers attributed this activity to the compound's ability to disrupt bacterial cell wall synthesis and inhibit essential enzymes.

Despite these promising findings, challenges remain in the clinical translation of 7-Bromo-2,4,6-trichloro-8-fluoroquinazoline-based therapeutics. Issues such as bioavailability, metabolic stability, and potential toxicity need to be addressed through further preclinical and clinical studies. However, the compound's unique structural features and versatile reactivity make it a valuable scaffold for future drug development efforts.

In conclusion, recent research on 7-Bromo-2,4,6-trichloro-8-fluoroquinazoline (CAS: 1698028-11-3) has highlighted its potential as a key intermediate and active pharmacophore in the development of kinase inhibitors, anticancer agents, and antimicrobials. Continued exploration of its chemical and biological properties is expected to yield new insights and therapeutic candidates in the coming years.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)